[MOL] For Leukemia Malignancies [01487] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] For Leukemia Malignancies



Good Morning My Friends,

Thought the following information may be of some use. Have a great day
and weekend.


Chimeric Therapies, Inc. Launches Pivotal Phase II/III Clinical Trial
for
Leukemia

LAGUNA NIGUEL, Calif., June 21 /PRNewswire/ -- Chimeric Therapies, Inc.
announced today the initiation of patient enrollment for its pivotal
Phase
II/III clinical trial to treat leukemias with allogeneic bone marrow
transplants from unrelated matched and mismatched donors.

Allogeneic bone marrow transplantation is a preferred curative approach
for
various types of leukemia provided that an exact immune match is found
among
the patient's relatives.  Since the probability for that ideal match is
approximately 30%, a transplant using unrelated matched and mismatched
donors
may be contemplated.  The disadvantage of this approach is an increased
risk
for graft failure or severe Graft-versus-Host Disease, two often fatal
complications.  In fact, older patients over the age of 50 are often
excluded
from this treatment due to these significant problems.  Therefore, less
than
4,000 allogeneic bone marrow transplants are performed annually in the
United
States despite a leukemia incidence of 29,000 cases and a mortality rate
of
21,000.

Chimeric Therapies has developed a cell engineering technology that
holds the
potential for making curative bone marrow transplants available to all
eligible patients, regardless of the availability of a matched related
donor.
As already practiced in other protocols, the patient's own leukemic bone
marrow must be eradicated with aggressive irradiation and chemotherapy. 
The
Company then processes the donor marrow with its proprietary technology
to
produce a cellular product that minimizes the potential for severe
Graft-versus-Host Disease and engrafts successfully when transplanted.

In its pivotal clinical trial, the Company is collaborating with
approximately twenty experienced transplant centers across the United
States
and is expecting to accrue over 200 patients to the clinical trial
during the
next eighteen months.  According to Dr. Steven Ford, Director of
Regulatory
and Clinical Affairs, "We will compare patients from the control group
and
the treatment group for incidence of severe Graft-versus-Host Disease
(GvHD),
time to engraftment of key bone marrow cells, and disease free survival
at
six months post-transplant."  Patients in the treatment group will have
their
donor's bone marrow processed by Chimeric Therapies.

The Company develops patented graft engineering and patient conditioning
methods to induce chimerism and immune tolerance in bone marrow and
solid
organ transplantation.  In addition to leukemia, it is pursuing heart
and
kidney transplantation protocols as well as other blood and autoimmune
disorders.

Chimeric Therapies, Inc., a venture capital-funded company with
corporate
headquarters in Laguna Niguel, California, was founded in May 1996.  It
operates a state of the art graft engineering facility in suburban
Philadelphia as well as a European wholly owned subsidiary located in
Munich,
Germany.

SOURCE  Chimeric Therapies, Inc.

CO:  Chimeric Therapies, Inc.

ST:  California

IN:  HEA MTC

SU:  PDT

06/21/99 08:15 EDT http://www.prnewswire.com

God Bless All,
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------